Prolonged exposure to homocysteine results in diminished but reversible pancreatic β-cell responsiveness to insulinotropic agents

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 4, 2007, Pages 324-334

  Patterson, Steven ^a   Scullion, Siobhan M J ^a   McCluskey, Jane T ^a   Flatt, Peter R ^a   McClenaghan, Neville H ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Homocysteine; Insulin secretion; Pancreatic cells

Indexed keywords

2 OXOISOCAPROIC ACID; ALANINE; ARGININE; CALCIUM ION; CHOLECYSTOKININ OCTAPEPTIDE; FORSKOLIN; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER 2; HOMOCYSTEINE; HYDROGEN PEROXIDE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PHORBOL 13 ACETATE 12 MYRISTATE; POTASSIUM CHLORIDE; SULFONYLUREA RECEPTOR 1; TOLBUTAMIDE; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LEVEL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; HYPERHOMOCYSTEINEMIA; INSULIN RELEASE; LONG TERM EXPOSURE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GLUCOSE; HOMOCYSTEINE; INSULIN; INSULIN-SECRETING CELLS; RATS; STIMULATION, CHEMICAL; TIME FACTORS;

EID: 34249779251     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.699     Document Type: Article

References (67)

1. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
2. Dalton ML, Gadson PF, Wrenn RW, Rosenquist TH. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703-711.
3. Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med 2001; 39: 666-674.
4. Medina M, Urdiales JL, Amores-Sanchez MI. Roles of homocysteine in cell metabolism: old and new functions. Eur J Biochem 2001; 268: 3871-3882.
5. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-389.
6. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-2081.
7. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98: 5-7.
8. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
9. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506-1511.
10. Becker A, Kostense PJ, Bos G, et al. Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. J Intern Med 2003; 253: 293-300.
11. van Guldener C, Stehouwer CD. Homocysteine and methionine metabolism in renal failure. Semin Vasc Med 2005; 5: 201-208.
12. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996; 122: 163-172.
13. Zhang C, Cai Y, Adachi MT, et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem 2001; 276: 35867-35874.
14. Hultberg B, Andersson A, Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicology 1997; 123: 33-40.
15. Kim WK, Pae YS. Involvement of N-methyl-D-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett 1996; 216: 117-120.
16. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997; 94: 5923-5928.
17. White AR, Huang X, Jobling MF, et al. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 2001; 76: 1509-1520.
18. Hultberg B, Andersson A, Isaksson A. Hypomethylation as a cause of homocysteine-induced cell damage in human cell lines. Toxicology 2000; 147: 69-75.
19. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999; 13: 2277-2283.
20. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000; 87: 45-51.
21. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000; 130: 377S-381S.
22. Jakubowski H. Protein N-homocysteinylation: implications for atherosclerosis. Biomed Pharmacother 2001; 55: 443-447.
23. Krumdieck CL, Prince CW. Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging. J Nutr 2000; 130: 365S-368S.
24. Jones BG, Rose FA, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994; 105: 165-170.
25. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signalling, and glutathione has a protective effect. J Mol Endocrinol 2001; 27: 85-91.
26. Moore P, El-sherbeny A, Roon P, Schoenlein PV, Ganapathy V, Smith SB. Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Exp Eye Res 2001; 73: 45-57.
27. Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002; 70: 694-702.
28. Lang J. Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion. Eur J Biochem 1999; 259: 3-17.
29. Ling Z, Pipeleers DG. Prolonged exposure of human beta cells to elevated glucose levels results in sustained cellular activation leading to a loss of glucose regulation. J Clin Invest 1996; 98: 2805-2812.
30. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998; 95: 2498-2502.
31. Grill V, Bjorklund A. Dysfunctional insulin secretion in type 2 diabetes: role of metabolic abnormalities. Cell Mol Life Sci 2000; 57: 429-440.
32. Briaud I, Harmon JS, Kelpe CL, Segu VB, Poitout V. Lipotoxicity of the pancreatic beta-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 2001; 50: 315-321.
33. Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003; 16: 5-22.
34. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44: 863-870.
35. Robertson RP, Harmon J, Tran POT, Poitout V. B-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53: S119-S124.
36. Malaisse WJ. The beta cell in NIDDM: giving light to the blind. Diabetologia 1994; 37: S36-S42.
37. Harmon JS, Gleason CE, Tanaka Y, Oseid EA, Hunter-Berger KK, Robertson RP. In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes 1999; 48: 1995-2000.
38. Tanaka Y, Gleason CE, Tran PO, Harmon JS, Robertson RP. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A 1999; 96: 10857-10862.
39. Prentki M, Corkey BE. Are the beta-cell signalling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 1996; 45: 273-283.
40. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc Natl Acad Sci U S A 1999; 96: 2327-2332.
41. Patterson S, Flatt PR, Brennan L, Newsholme P, McClenaghan NH. Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic β-cell glucose metabolism and insulin secretion. J Endocrinol 2006; 189: 301-310.
42. McClenaghan NH, Barnett CR, Ah-Sing E, et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996; 45: 1132-1140.
43. McClenaghan NH, Gray AM, Barnett CR, Flatt PR. Hexose recognition by insulin-secreting BRIN-BD11 cells. Biochem Biophys Res Commun 1996; 223: 724-728.
44. McClenaghan NH, Barnett CR, O'Harte FP, Flatt PR. Mechanisms of amino acid-induced insulin secretion from the glucose-responsive BRIN-BD11 pancreatic B-cell line. J Endocrinol 1996; 151: 349-357.
45. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981; 20: 573-577.
46. Zhou M, Diwu Z, Panchuk-Voloshina N, Haugland RP. A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidases. Anal Biochem 1997; 253: 162-168.
47. Lees Murdock DJ, Barnett YA, Barnett CR. DNA damage and cytotoxicity in pancreatic β-cells expressing human CYP2E1. Biochem Pharmacol 2004; 68: 523-530.
48. Picton SF, McCluskey JT, Flatt PR, McClenaghan NH. Effects of cytotoxic agents on functional integrity and antioxidant enzymes in clonal beta-cells. Diabetes Metab 2002; 28: 3S70-3S77 & 3S108-3S112.
49. McClenaghan NH, Flatt PR. Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines. Diabetes Obes Metab 1999; 1: 137-150.
50. Rorsman P. The pancreatic beta-cell as a fuel sensor: an electrophysiologist's viewpoint. Diabetologia 1997; 40: 487-495.
51. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20: 6920-6926.
52. Streck EL, Matte C, Vieira PS, et al. Impairment of energy metabolism in hippocampus of rats subjected to chemically-induced hyperhomocysteinemia. Biochim Biophys Acta 2003; 1637: 187-192.
53. Malloy CR, Sherry AD, Jeffrey FM. Analysis of tricarboxylic acid cycle of the heart using 13C isotope isomers. Am J Physiol 1990; 259: H987-H995.
54. Hutton JC, Atwater I, Malaisse WJ. Fuel and signal function of 2-keto acids in insulin secretion. Horm Metab Res Suppl 1980; 10: 31-37.
55. Yada T. Action mechanisms of amino acids in pancreatic β-cells. In Frontiers of Insulin Secretion and Pancreatic B-Cell Research, Flatt PR, Lenzen S (eds). Smith-Gordon: London, 1994; 129-134.
56. + channels in human isolated pancreatic B-cells. FEBS Lett 1987; 215: 9-12.
57. 2+ signalling and insulin release in human pancreatic beta cells. Diabetologia 1994; 37: S11-S20.
58. + ATPase activity in hippocampus of rats subjected to chemically induced hyperhomocysteinemia. Neurochem Res 2002; 27: 1593-1598.
59. Ashfield R, Gribble FM, Ashcroft SJ, Ashcroft FM. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the K(ATP) channel. Diabetes 1999; 48: 1341-1347.
60. Kashima Y, Miki T, Shibasaki T, et al. Critical role of cAMP-GEFII-Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 2001; 276: 46046-46053.
61. Ahren B, Karlsson S. Role of islet neuropeptides in the regulation of insulin secretion. In Frontiers of Insulin Secretion and Pancreatic B-Cell Research, Flatt PR, Lenzen S (eds). Smith-Gordon: London, 1994; 313-318.
62. Verspohl EJ, Herrmann K. Involvement of G proteins in the effect of carbachol and cholecystokinin in rat pancreatic islets. Am J Physiol 1996; 271: E65-E72.
63. Tyagi N, Moshal KS, Ovechkin AV, et al. Mitochondrial mechanism of oxidative stress and systemic hypertension in hyperhomocysteinemia. J Cell Biochem 2005; 96: 665-671.
64. Tyagi N, Sedoris KC, Steed M, et al. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol 2005; 289: H2649-H2656.
65. Siow YL, Au-Yeung KK, Woo CW, OK. Homocysteine stimulates phosphorylation of NADPH oxidase p47phox and p67phox subunits in monocytes via protein kinase Cbeta activation. Biochem J 2006; 398: 73-82.
66. Patterson S, Flatt PR, McClenaghan NH. Homocysteine and other structurally-diverse amino thiols can alter pancreatic beta cell function without evoking cellular damage. Biochim Biophys Acta 2006; 1760: 1109-1114.
67. Di Simplicio P, Frosali L, Priora R, et al. Biochemical and biological aspects of protein thiolation in cells and plasma. Antioxid Redox Signal 2005; 7: 951-963.